Short Interest in BioAge Labs, Inc. (NASDAQ:BIOA) Drops By 34.5%

BioAge Labs, Inc. (NASDAQ:BIOA) was the recipient of a significant drop in short interest during the month of July. As of July 15th, there was short interest totaling 2,451,099 shares, a drop of 34.5% from the June 30th total of 3,744,445 shares. Currently, 6.7% of the shares of the company are short sold. Based on an average trading volume of 540,360 shares, the short-interest ratio is presently 4.5 days.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Wall Street Zen lowered BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. BTIG Research began coverage on BioAge Labs in a research note on Wednesday, May 13th. They issued a “buy” rating and a $40.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, July 21st. Finally, Roth Capital initiated coverage on BioAge Labs in a research report on Wednesday, May 27th. They set a “buy” rating and a $36.00 price objective on the stock. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, BioAge Labs has an average rating of “Moderate Buy” and a consensus target price of $43.50.

BioAge Labs Price Performance

NASDAQ:BIOA traded down $14.72 during trading hours on Friday, reaching $10.13. 2,299,028 shares of the company were exchanged, compared to its average volume of 618,881. The company has a market capitalization of $450.46 million, a P/E ratio of -4.23 and a beta of 0.61. BioAge Labs has a 1-year low of $4.11 and a 1-year high of $25.95. The business has a 50 day moving average of $20.76 and a 200 day moving average of $19.59.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.19. The firm had revenue of $2.77 million during the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. As a group, equities research analysts anticipate that BioAge Labs will post -2.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioAge Labs

Several institutional investors and hedge funds have recently bought and sold shares of the company. Stempoint Capital LP acquired a new stake in BioAge Labs during the first quarter worth about $5,923,000. Octagon Capital Advisors LP increased its holdings in BioAge Labs by 9.4% in the 1st quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock valued at $30,573,000 after buying an additional 150,000 shares during the period. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of BioAge Labs in the 4th quarter valued at approximately $1,058,000. Y Intercept Hong Kong Ltd acquired a new position in shares of BioAge Labs in the 1st quarter valued at approximately $3,521,000. Finally, Militia Capital Management LLC bought a new stake in shares of BioAge Labs during the 1st quarter worth approximately $565,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.